Xeris Biopharma beats Q2 revenue expectations, raises FY guidance

Xeris Biopharma Holdings

07/08/2025 12:28

Overview

Xeris Biopharma Q2 revenue grows 49% YoY to $71.5 mln, driven by Recorlev

Product revenue for Q2 beats analyst expectations, per LSEG data

Company raises full-year revenue guidance to $280-$290 mln

Outlook

Xeris raises full-year 2025 revenue guidance to $280-$290 mln

Company projects $750 mln total revenue by 2030

Xeris expects Recorlev net revenue to reach $1 bln by 2035

Company anticipates XP-8121 peak net revenue of $1-$3 bln

Result Drivers

RECORLEV DEMAND - Revenue growth driven by 136% increase in Recorlev sales due to higher patient numbers

GVOKE PRESCRIPTIONS - 17% revenue increase attributed to prescription growth and favorable pricing

KEVEYIS SHIPMENTS - 13% revenue decline due to reduced product shipments

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
Beat
$67.71 mln
$64.60 mln (4 Analysts)
Q2 Net Income
-$1.93 mln
Q2 Basic EPS
-$0.01
Q2 Operating Income
$4.48 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Xeris Biopharma Holdings Inc is $7.00, about 21.6% above its August 6 closing price of $5.49

Press Release: ID:nBw6Q6N22a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)